Literature DB >> 16691430

Lack of association with TNF-alpha-308 promoter polymorphism in patients with vitiligo.

Ayca Cordan Yazici1, M Emin Erdal, Tamer Irfan Kaya, Guliz Ikizoglu, Kaan Savasoglu, Handan Camdeviren, Umit Tursen.   

Abstract

Vitiligo is an acquired depigmentary disorder of the skin, characterized by incomplete penetrance, multiple susceptibility loci and genetic heterogeneity. An immunologic hypothesis is currently advanced as a possible pathogenesis of vitiligo. The cytokines have an important role in pathogenesis of autoimmunity in which tumor necrosis factor-alpha (TNF-alpha), a paracrine inhibitor of melanocytes, is especially important. Several single-nucleotide polymorphisms (SNP) have been identified in the human TNF gene promoter. The polymorphism at position -308 (TNF-308), which involves substituting G for A and designing the AA genotype, leads to a higher rate of TNF gene transcription than the wild-type GG genotype in in vitro expression studies. It has also been linked to increased susceptibility to several chronic metabolic, degenerative, inflammatory and autoimmune diseases. Therefore, we investigated the TNF-alpha-308 SNP in patients with vitiligo. We examined 61 patients with vitiligo. Healthy age-, ethnically- and sex-matched individuals (n = 123) served as controls. Polymerase chain reaction amplification was used for analysis of the polymorphism at position -308 in promoter of TNF-alpha gene. We found that the distribution of TNF-alpha genotypes in vitiligo patients did not differ from that in control subjects (P > 0.05). Moreover, there was no association between TNF-alpha genotypes and types of vitiligo. In conclusion, we suggest that TNF-alpha-308 SNP is not a genetic risk factor for vitiligo susceptibility.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16691430     DOI: 10.1007/s00403-006-0664-2

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  6 in total

1.  Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP.

Authors:  Stanca A Birlea; Ying Jin; Dorothy C Bennett; Deborah M Herbstman; Margaret R Wallace; Wayne T McCormack; E Helen Kemp; David J Gawkrodger; Anthony P Weetman; Mauro Picardo; Giovanni Leone; Alain Taïeb; Thomas Jouary; Khaled Ezzedine; Nanja van Geel; Jo Lambert; Andreas Overbeck; Pamela R Fain; Richard A Spritz
Journal:  J Invest Dermatol       Date:  2010-11-18       Impact factor: 8.551

2.  Effect of TNF-α -308G/A (rs1800629) Promoter Polymorphism on the Serum Level of TNF-α Among Iraqi Patients with Generalized Vitiligo.

Authors:  Ronak Ahmed; Dana Sharif; Mohammad Jaf; Dashty Mohammed Amin
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-11-13

3.  Tumor necrosis factor-α -308G/A polymorphism is associated with active vitiligo vulgaris in a northeastern Mexican population.

Authors:  Mauricio Salinas-Santander; Daniel Díaz-García; Augusto Rojas-Martínez; Cristina Cantú-Salinas; Celia Sánchez-Domínguez; Miguel Reyes-López; Ricardo M Cerda-Flores; Jorge Ocampo-Candiani; Rocío Ortiz-López
Journal:  Exp Ther Med       Date:  2012-03-09       Impact factor: 2.447

4.  Novel approaches to vitiligo treatment via modulation of mTOR and NF-κB pathways in human skin melanocytes.

Authors:  Jerry Wan; Fuquan Lin; Wei Zhang; Aie Xu; Joseph DeGiorgis; Hongguang Lu; Yinsheng Wan
Journal:  Int J Biol Sci       Date:  2017-02-25       Impact factor: 6.580

5.  Therapeutic effects of iNOS inhibition against vitiligo in an animal model.

Authors:  Hamid Mansourpour; Katayoun Ziari; Sahar Kalantar Motamedi; Amin Hassan Poor
Journal:  Eur J Transl Myol       Date:  2019-08-06

6.  Increased Tumor Necrosis Factor (TNF)-α and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo.

Authors:  Naresh C Laddha; Mitesh Dwivedi; Rasheedunnisa Begum
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.